So apparently we did not exclude what we thought didn't work in PII ?
Meanwhile, in order to hit 298 when we did, the efficacy in the "subgroup" has to be rather dramatic if it is more or less 50% of the test group.
It won't be like NWBO because, I think, the signal is much stronger. If this pans out like this then we did not extend life a little bit in the subgroup, but a lot, more than Fosco's suggestion there (but for the subgroup)
That might sound like the word "cure" for those.
...
Then if the "target" can be introduced to the other 50% as per the article about Dendreon and anti-cancer vaccine... that would be next.